Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

PFE vs MRNA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PFE Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 7–3 Matrix Metrics)

PFE Overall Winner 6-Pillar Tally: PFE 5 – 1 MRNA Matrix Metrics: PFE 7 – 3 MRNA

As of Nov 20, 2026, Pfizer Inc. (PFE) is the stronger overall head-to-head candidate over Moderna, Inc. (MRNA) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). PFE carries a Unified Composite Score of 49.4/100 (HOLD) at $27.40 (9.3x Forward P/E, 29.1% operating margin), whereas MRNA carries 40.3/100 (SELL) at $195.00 (23.0x Forward P/E, -80.8% operating margin).

  • Growth vs. Quality Trade-Off: PFE earns the overall head-to-head edge with a stronger Unified Composite Score (49.4/100 HOLD vs. MRNA 40.3/100 SELL) and 0.18β · 22% Vol risk profile, whereas MRNA leads top-line expansion (+29.2% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PFE vs MRNA
PFE NYSE Head-to-Head Winner
Pfizer Inc.
Pharmaceutical Preparations
$27.40
-0.51% 1D
Market Cap $157.0B
TTM Revenue $63.6B
Forward P/E 9.3x
Beta / 30D Vol 0.18β · 22% Vol
Unified Composite Score
49.4 / 100 HOLD
Tech 30.0 Fund 51.0 Flow 68.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 32
RSI-14: 32.5 · SMA20: $29.32 · SMA50: $28.82
MRNA NASDAQ
Moderna, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$195.00
-2.17% 1D
Market Cap $80.7B
TTM Revenue $2.52B
Forward P/E 23.0x
Beta / 30D Vol 2.23β · 78% Vol
Unified Composite Score
40.3 / 100 SELL
Tech 18.0 Fund 42.0 Flow 67.0 Mom 46.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 41
RSI-14: 41.5 · SMA20: $225.26 · SMA50: $207.89

6-Pillar Scorecard Institutional Category Breakdown (PFE 5 – 1 MRNA)

Columns: Metric · PFE · MRNA
1. Valuation Multiples PFE
Forward P/E 9.3x 23.0x
Trailing P/E 39.3x 23.0x
PEG Ratio 8.56x N/M
EV / Revenue 3.4x 33.1x
2. Growth & Scale PFE
Revenue Growth (YoY) -0.4% +29.2%
Earnings Growth (YoY) -9.7% -85.1%
TTM Revenue (USD) $63.6B $2.52B
Market Cap $157.0B $80.7B
3. Profitability & Quality PFE
Gross Margin 74.9% -42.0%
Operating Margin 29.1% -80.8%
Net Profit Margin 6.3% -110.5%
Return on Equity (ROE) 4.5% -34.5%
4. Balance Sheet & Cash Flow PFE
Cash Generation (TTM) $11.8B -$2.04B
Cash Flow Margin 18.5% -81.0%
Net Cash / Leverage $60.8B Net Debt (0.70x D/E) $3.03B Net Debt (0.62x D/E)
Dividend Yield 7.66% None (0.00%)
5. Options & Positioning PFE
Options Structure Phase CONSOLIDATION CONSOLIDATION
Current IV / %ile 48.1% (58th %ile) 89.6% (52nd %ile)
Put/Call OI Skew 0.62x (Call-Skewed) 1.05x (Balanced)
OBV Trend / Tech Phase DISTRIBUTION · Neutral DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat MRNA
OpEx & R&D Intensity 45.8% of Rev ($29.1B) 38.8% of Rev ($980M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - General Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PFE (7) vs MRNA (3)
Institutional Metric PFE MRNA Criterion Row Edge
Market Capitalization
Scale
$157.0B $80.7B Larger Scale PFE
Trailing P/E Ratio
Valuation
39.3x 23.0x Lower Multiple MRNA
Forward P/E Ratio
Valuation
9.3x 23.0x Lower Multiple PFE
Revenue Growth (YoY)
Growth
-0.4% +29.2% Higher Growth MRNA
Operating Margin (TTM)
Profitability
29.1% -80.8% Higher Margin PFE
Net Profit Margin
Profitability
6.3% -110.5% Higher Margin PFE
Return on Equity (ROE)
Capital Efficiency
4.5% -34.5% Higher ROE PFE
52-Week Range Position
Momentum
48% ($24–$31) 67% ($22–$281) Stronger Trend MRNA
Beta / 30D Volatility
Risk Regime
0.18β · 22% Vol 2.23β · 78% Vol Lower Realized Risk PFE
Unified Institutional Score
Composite Signal
49.4 / 100 (HOLD) 40.3 / 100 (SELL) Higher Composite PFE
Trailing 12M Revenue (USD)
Operating Scale
$63.6B $2.52B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
74.9% -42.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
8.56x PEG · 3.4x EV/Rev N/M PEG · 33.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$11.8B ($60.8B Net Debt (0.70x D/E)) -$2.04B ($3.03B Net Debt (0.62x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MRNA +6.16 pp
PFE: -9.93% · MRNA: -3.77%
3M Horizon MRNA +42.44 pp
PFE: -2.04% · MRNA: +40.4%
6M Horizon MRNA +310.17 pp
PFE: +5.79% · MRNA: +315.96%
1Y Horizon MRNA +696.32 pp
PFE: +10.13% · MRNA: +706.45%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period PFE Revenue MRNA Revenue PFE Op. Margin MRNA Op. Margin Margin Leader
FY2018 $40.8B $140M 27.3% -306.0% PFE
FY2019 $40.9B $60M 39.2% -906.8% PFE
FY2020 $41.6B $800M 22.0% -95.0% PFE
FY2021 $73.6B $18.5B 29.8% 72.0% MRNA
FY2022 $91.8B $19.3B 34.2% 48.9% MRNA
FY2023 $50.9B $6.85B 4.2% -61.9% PFE
FY2024 $63.6B $3.24B 12.6% -121.9% PFE
FY2025 $62.6B $1.94B 12.4% -158.1% PFE

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PFE CONSOLIDATION
56d in phase · OBV DISTRIBUTION
Current IV 48.1%
IV Percentile 58th %ile
Put/Call OI Skew 0.62x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact PFE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MRNA CONSOLIDATION
22d in phase · OBV DISTRIBUTION
Current IV 89.6%
IV Percentile 52nd %ile
Put/Call OI Skew 1.05x (Balanced)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact MRNA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $28.86 · IV 25.6%

PFE vs. MRNA: Simulated 5-Day Option Payoffs & Capital Efficiency

Compare 100 shares of PFE ($2,886) vs. MRNA ($21,527) against risk-defined 5-day vertical and put-wall option structures.

PFE Spot $28.86 · IV 25.6%
PFE Options Simulator →
5-DAY BULLISH SWING Liq A

Dec 18 $29 / $30 Bull Call Spread

Buy 2x $29C · Sell 2x $30C · 31d

Net Entry $84 Debit
T+5d @ +5% Move +$52 (+62%)
Max Risk / Buffer $84 Capped
5d Edge & Liquidity 0.9x R:R · Liq A
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq A

Jan 15 '27 $27 / $25 Bull Put Spread

Sell 2x $27P · Buy 2x $25P · 59d

Net Entry $58 Credit
Max Credit / Yield +$58 (+17.0% RoM)
Max Risk / Buffer -7.4% Cushion ($342 Mgn)
5d Edge & Liquidity 77% PoP · Liq A
Simulate 5-Day Payoff →
MRNA Spot $215.27 · IV 83.7%
MRNA Options Simulator →
5-DAY BULLISH SWING Liq A

Dec 18 $220 / $260 Bull Call Spread

Buy 1x $220C · Sell 1x $260C · 32d

Net Entry $1,105 Debit
T+5d @ +5% Move +$267 (+24%)
Max Risk / Buffer $1,105 Capped
5d Edge & Liquidity 0.7x R:R · Liq A
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq A

Dec 18 $190 / $180 Bull Put Spread

Sell 1x $190P · Buy 1x $180P · 32d

Net Entry $255 Credit
Max Credit / Yield +$255 (+34.2% RoM)
Max Risk / Buffer -12.9% Cushion ($745 Mgn)
5d Edge & Liquidity 74% PoP · Liq A
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PFE Moat Profile Scale & Operating Efficiency Moat
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $157.0B market capitalization and 29.1% operating margin.
OpEx & R&D Reinvestment 45.8% of Rev ($29.1B)
90D Engineering Disclosures 0 Published
MRNA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $80.7B market capitalization and -80.8% operating margin.
OpEx & R&D Reinvestment 38.8% of Rev ($980M)
90D Engineering Disclosures 0 Published · mRNA Therapeutics

Investor FAQ PFE vs MRNA Key Questions & Quantitative Answers

As of Nov 20, 2026, Pfizer Inc. (PFE) is the stronger overall head-to-head candidate over Moderna, Inc. (MRNA) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). PFE carries a Unified Composite Score of 49.4/100 (HOLD) at $27.40 (9.3x Forward P/E, 29.1% operating margin), whereas MRNA carries 40.3/100 (SELL) at $195.00 (23.0x Forward P/E, -80.8% operating margin). Growth vs. Quality Trade-Off: PFE earns the overall head-to-head edge with a stronger Unified Composite Score (49.4/100 HOLD vs. MRNA 40.3/100 SELL) and 0.18β · 22% Vol risk profile, whereas MRNA leads top-line expansion (+29.2% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.

PFE leads the Growth & Scale pillar: PFE posts -0.4% YoY revenue growth and -9.7% YoY earnings growth on $63.6B TTM revenue (74.9% gross margin, 29.1% operating margin), compared with MRNA at +29.2% YoY revenue growth and -85.1% YoY earnings growth on $2.52B TTM revenue (-42.0% gross margin, -80.8% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), PFE cumulative revenue shifted +53.3% while MRNA shifted +1285.7%. In operating R&D and SG&A reinvestment, PFE deploys 45.8% of Rev ($29.1B) (0 90-day corporate R&D disclosures) versus 38.8% of Rev ($980M) (0 disclosures) for MRNA.

PFE screens cheaper on headline valuation multiples. PFE trades at 9.3x Forward P/E, 39.3x Trailing P/E, 8.56x PEG, and 3.4x EV/Revenue (18.5% FCF margin), whereas MRNA trades at 23.0x Forward P/E, 23.0x Trailing P/E, N/M PEG, and 33.1x EV/Revenue (-81.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PFE (4.5% ROE) versus MRNA (-34.5% ROE) capital efficiency.

In options market volatility and institutional positioning, PFE carries 48.1% implied volatility (58th %ile, Balanced (25th–60th %ile)), a 0.62x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.18β · 22% Vol realized risk). By comparison, MRNA carries 89.6% implied volatility (52nd %ile, Balanced (25th–60th %ile)), a 1.05x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (2.23β · 78% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.